Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 15/20 | 0.81 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | IGF1R | P08069 | 1/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.46 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.46 |
| ▸ | CTSC | P53634 | 1/20 | 0.46 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12964737 | 0.89 | AXL (1.00) | AXLEGFRFGFR1 | |
| SCHEMBL25549992 | 0.76 | AXL (0.54) | AXLFGFR1JAK2IGF1RAURKB | |
| SCHEMBL270946 | 0.74 | AXL (0.80) | AXLJAK2IGF1RAURKBALK | |
| SCHEMBL265260 | 0.73 | BRD4 (0.77) | AXL | |
| SCHEMBL12964809 | 0.72 | AXL (1.00) | AXLJAK2IGF1RAURKBALK | |
| SCHEMBL12813376 | 0.72 | AXL (1.00) | AXLKDR | |
| SCHEMBL25550759 | 0.71 | AXL (0.58) | AXLFGFR1JAK2IGF1RAURKB | |
| SCHEMBL12964729 | 0.71 | AXL (1.00) | AXLFGFR1 | |
| SCHEMBL12964797 | 0.71 | AXL (0.78) | AXLFGFR1FGFR4KDR | |
| SCHEMBL25549964 | 0.71 | AXL (0.73) | AXLFGFR1JAK2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230165857-A1 | AXL KINASE INHIBITORS AND USE OF THE SAME | SUMITOMO PHARMA ONCOLOGY, INC. | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165857-A1 | AXL KINASE INHIBITORS AND USE OF THE SAME | AXL, FLT3, TEC | AXL 1/4885EGFR 29/4885FGFR1 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.